Dr M. Iftakhar Alam
I am currently appointed as Associate Professor of Applied Statistics at the Institute of Statistical Research and Training, University of Dhaka. Earlier I obtained Bachelor and Master degrees in Applied Statistics. I truly started research career as a PhD student at the School of Mathematical Sciences, Queen Mary University of London, UK, where I looked at Optimal Adaptive designs for dose finding in early phase Clinical trials, under the supervision of Dr. Barbara Bogacka and Dr. D. Stephen Coad. My current research focuses on the various aspects of dose finding in early phase clinical trials.
- Alam, M. I. and Sultana, Jafrin. Isotonic design for phase I clinical trials: can we improve further? (Accepted for Austrian Journal of Statistics).
- Alam, M. I. and M. Mansur (2018). A dynamic stopping rule for phase I clinical trials. Biometrical Letters 55(1), 17-30.
- Moni, M. M. and M. I. Alam (2018). Patient-specific dose finding in phase I clinical trials. Journal of Applied Statistics, 1-12.
- Alam, M. I., B. Bogacka, and D. Stephen Coad (2017). Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials. Computational Statistics and Data Analysis 111, 183-202.
- Alam, M. I. and M. I. Hossain (2017). On performance of the 3+3 design and its modified versions for dose finding in phase I clinical trials, Journal of Data Science 15 (1), 115-128.
- Alam, M. I (2016). A comparison between the continual reassessment method and D-optimum design for dose finding in phase I clinical trials. Biometrical Letters 53 (2), 69-82.
- A Comparison Between the Continual Reassessment Method and D-optimum Design for Dose Finding in Phase I Clinical Trials, 37th Annual Conference of the International Society for Clinical Biostatistics, Birmingham, UK, August 2016.
- A Constrained Optimum Adaptive Design for Dose Finding in Early Phase Clinical Trials, 35th Annual Conference of the Society for Clinical Trials, Philadelphia, Pennsylvania, USA, May 2014.
- Adaptive Dose Finding in Early Phase Clinical Trials Incorporating Pharmacokinetic Information, 34th Annual Conference of the International Society for Clinical Biostatistics, Munich, Germany, August 2013.
- Adaptive Dose Finding in Early Phase Clinical Trials Incorporating Pharmacokinetic Information, Population Optimum Design of Experiments Workshop, Eli Lilly, UK, June 2013.
- Dose Finding in Early Phase Clinical Trials Incorporating Pharmacokinetic Information, 36th Research Students’ Conference in Probability, Statistics and Social Statistics, Lancaster University, UK, March 2013
- Conference Award for Scientists, 37th Annual Meeting of the International Society for Clinical Biostatistics, Birmingham, UK, August 2016.
- Student Conference Award, 34th Annual Meeting of the International Society for Clinical Biostatistics, Munich, Germany, August 2013.
- Fazlul Huq Hall Provost Award, University of Dhaka, Bangladesh, 2004.
- Adaptive dose modification in seamless phase I/II clinical trials: Usually early phase clinical trials start with a discrete set of doses determined from the pre-clinical studies to find the maximum tolerated dose. There is a chance that the dose vector may not contain the true dose that should be recommended for further investigation in the next phase. Chu et al. in their paper published in Statistics in Medicine in 2015, proposed a methodology to identify the right dose in case it lies in the middle of two available doses. Their methodology can be extended to include seamless phase I/II trials to find the optimum dose in such situations.
- AST 130: Statistical Computing I
- AST 330: Data Analysis Using SPSS, SAS, and Stata
- AST 524: Clinical Trials
- Member, International Society for Clinical Biostatistics, Denmark.
- Member, International Statistical Institute, The Hague, The Netherlands.
- Life Member, Bangladesh Statistical Association.